Cowen Reiterates Neutral Following Hortonworks (HDP) Q1 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall St slides after strong jobs report bolsters hawkish Fed bets
- US nonfarm payrolls surge in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil slides on Friday, heads for weekly gain on US-Iran fight
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
After-Hours Stock Movers 05/12: (HDP) (TUBE) (VRTX) Higher; (OREX) (VSLR) (GDDY) Lower (more...)
May 12, 2015 6:10 PM EDTFibrocell Science, Inc., (Nasdaq: FCSC) 18% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation for Fibrocell's lead orphan gene-therapy drug candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). The rare pediatric disease designation augments the Orphan Drug designation granted by the FDA and announced by Fibrocell in June 2014 for FCX-007 to treat dystrophic epidermolysis bullosa (DEB), which includes RDEB.
Hortonworks (HDP) Tops Q1 EPS by 9c
May 12, 2015 4:02 PM EDTHortonworks (NASDAQ: HDP) reported Q1 EPS of ($0.77), $0.09 better than the analyst estimate of ($0.86). Revenue for the quarter came in at $22 million versus the consensus estimate of $18.2 million.
For earnings history and earnings-related data on Hortonworks (HDP) click here.
... More